Increased systolic blood pressure and insulin resistance partially mediated relationship
Semaglutide Can Cut Prevalence of Obesity, CVD in Eligible U.S. Adults
Applying STEP 1 treatment would result in a 46.1 percent reduction in obesity prevalence and 17.8 percent relative risk reduction in CVD